PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.

Albert Gris-OliverYasir H IbrahimMartín A RivasCelina García-GarcíaMònica Sánchez-GuixéFiorella Ruiz-PaceCristina ViaplanaJosé M Pérez-GarcíaAntonio Llombart-CussacJudit GruesoMireia ParésMarta GuzmánOlga RodríguezPilar AntonPatricia CozarMaria Teresa CalvoAlejandra BrunaJoaquín ArribasCarlos CaldasRodrigo DienstmannPaolo NuciforoMafalda OliveiraJavier Cortes Violeta Serra

Published in: British journal of cancer (2021)

PI3K pathway activation induces primary resistance or early adaptation to eribulin, supporting the combination of PI3K inhibitors and eribulin for the treatment of HER2- BC patients.

Keyphrases

metastatic breast cancer
end stage renal disease
phase ii
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
clinical trial
combination therapy